World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: Acute and continuation treatment of major depressive disorder

World Journal of Biological Psychiatry

Volumn 3, Issue 1, 2002, Pages 5-43

  Bauer, Michael ^a   Whybrow, Peter C ^a   Angst, Jules ^b   Versiani, Marcio ^c   Möller, Hans Jürgen ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

acute treatment; antidepressants; biological treatment; continuation treatment; evidence based guidelines; major depressive disorder; pharmacotherapy

Indexed keywords

ANTIDEPRESSANT AGENT;

ADOLESCENT; ADULT; BRAIN; CHILD; CLASSIFICATION; DEPRESSION; DRUG COMBINATION; DRUG MONITORING; DRUG POTENTIATION; ELECTROCONVULSIVE THERAPY; FEMALE; HEALTH; HUMAN; INTERNATIONAL COOPERATION; MAJOR DEPRESSION; MALE; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PRACTICE GUIDELINE; PSYCHIATRY; PSYCHOTHERAPY; REVIEW;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; BIOLOGICAL PSYCHIATRY; BRAIN; CHILD; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; DRUG MONITORING; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ELECTROCONVULSIVE THERAPY; FEMALE; GUIDELINES; HUMANS; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; PSYCHOTHERAPY; WORLD HEALTH;

EID: 0036047459     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622970209150599     Document Type: Article

References (370)

1. Adli M, Berghöfer A, Linden M, Helmchen H, Müller-Oerlinghausen B, Mackert A, Stamm T, Bauer M (2002) Effectiveness and feasibility of a standardized stepwise drug treatment algorithm for inpatients with depressive disorders - results of a two-year observational study. J Clin Psychiatry, In Press.
2. AHCPR (Agency for Health Care Policy and Research) (1993) Depression Guidelines Panel. Depression in Primary Care: Clinical Practice Guideline No. 5. AHCPR pub. No. 93-0550. Rockville, MD.
3. AHCPR (Agency for Health Care Policy and Research) (1999) Evidence Report on Treatment of Depression: Newer Pharmacotherapies. San Antonio Evidence-Based Practice Center. Washington, DC, AHCPR, Evidence-Based Practice Centers. AHCPR pub. No. 99-E014.
4. Allain H, Schuck S, Mauduit N (2000) Depression in Parkinson's disease. BMJ 320:1287-1288.
5. Altar CA (1999) Neurotrophins and depression. Trends Pharmacol Sci 20:59-61.
6. Altshuler LL, Cohen L, Szuba MP, Burt VK, Gitlin M, Mintz J (1996) Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 153:592-606.
7. Altshuler LL, Cohen LS, Moline ML, Kahn DA, Carpenter D, Docherty JP, and The Expert Consensus Panel for Depression in Women (2001) The Expert consensus guideline series: treatment of depression in women. Postgrad Med Special Report 2001(March):1-116.
8. American Academy of Child and Adolescent Psychiatry (1998) Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 37(Suppl):63S-83S.
9. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th revision (DSM-IV). American Psychiatric Press, Washington DC.
10. American Psychiatric Association (2000) Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 157(Suppl):1-45.
11. American Psychiatric Association Task Force on Electroconvulsive Therapy (1990) The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging. AP Press, Washington, DC.
12. Amsterdam JD (1991) (ed) Advances in Neuropsychiatry and Psychopharmacology, Vol 2: Refractory Depression. Raven Press, New York.
13. Amsterdam JD, Hornig-Rohan M (1996) Treatment algorithms in treatment-resistant depression. Psychiatr Clin North Am 19:371-386.
14. Amsterdam JD, Maislin G, Potter L (1994) Fluoxetine efficacy in treatment resistant depression. Prog Neuropsychopharmacol Biol Psychiatry 18:243-261.
15. Andersen G, Vestergaard K, Lauritzen L (1994) Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 25:1099-1104.
16. Anderson IM (2000) Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 58:19-36.
17. Anderson IM (2001) Meta-analytical studies on new antidepressants. Br Med Bull 57:161-178.
18. Anderson IM, Nutt DJ, Deakin JF (2000) Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology. J Psychopharmacol 14:3-20.
19. Angst J (1986) The course of affective disorders. Psychopathology 19(Suppl 2):47-52.
20. Angst J (1999a) Major depression in 1998: are we providing optimal therapy? J Clin Psychiatry 60(Suppl 6):5-9.
21. Angst J (1999b) Suicide risk in patients with major depressive disorder. J Clin Psychiatry 60(Suppl 2):57-62.
22. Angst J, Preisig M (1995) Course of a clinical cohort of unipolar, bipolar and schizoaffective patients. Results of a prospective study from 1959 to 1985. Schweiz Arch Neurol Psychiatr 146:5-16.
23. Angst J, Stabl M (1992) Efficacy of moclobemide in different patient groups: a meta-analysis of studies. Psychopharmacology (Berl) 106(Suppl):S109-S113.
24. Appleby L (1992) Suicide in psychiatric patients: risk and prevention. Br J Psychiatry 161:749-758.
25. Argyropoulos SV, Nutt DJ (2000) Substance P antagonists: novel agents in the treatment of depression. Expert Opin Investig Drugs 9:1871-1875.
26. Aronson R, Offman HJ, Joffe RT, Naylor D (1996) Triiodothyronine augmentation in the treatment of refractory depression. A metaanalysis. Arch Gen Psychiatry 53:842-848.
27. Artigas F, Romero L, de Montigny C, Blier P (1996) Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 19:378-383.
28. Ayuso Gutierrez JL, Alino JJ (1971) Tryptophan and an MAOI (nialamide) in the treatment of depression. A double-blind study. Int Pharmacopsychiatry 6:92-97
29. Bakish D (1999) The patient with comorbid depression and anxiety: the unmet need. J Clin Psychiatry 60(Suppl 6):20-24.
30. Bakker A, van Balkom AJ, van Dyck R (2000) Selective serotonin reuptake inhibitors in the treatment of panic disorder and agoraphobia. Int Clin Psychopharmacol 15(Suppl 2):S25-S30.
31. Barbui C, Hotopf M (2001) Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials. Br J Psychiatry 178:129-144.
32. Barden N, Reul JM, Holsboer F (1995) Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system? Trends Neurosci 18:6-11.
33. Bauer M, Hellweg R, Gräf KJ, Baumgartner A (1998) Treatment of refractory depression with high-dose thyroxine. Neuropsychopharmacology 18:444-455.
34. Bauer M, Döpfmer S (1999) Lithium augmentation in treatmentresistant depression - A meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 19:427-434.
35. Bauer M, Bschor T, Kunz D, Berghöfer A, Ströhle S, Müller-Oerlinghausen B (2000) Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry 157:1429-1435.
36. Bauer M, Helmchen H (2000) General principles of the treatment of depressive and manic disorders. In: Helmchen H, Henn F, Lauter H, Sartorius N (eds) Contemporary Psychiatry. Vol. 3. Springer, Heidelberg, pp 305-316.
37. Bauer M, Whybrow PC (2001) Thyroid hormone, neural tissue and mood modulation. World J Biol Psychiatry 2:57-67.
38. Bauer M, Whybrow PC, Angst J, Versiani M, Möller HJ, WFSBP Task Force on Unipolar Depressive Disorders (In Press) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry.
39. Baumann P (1996) Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 31:444-469.
40. Baumann P, Nil R, Souche A, Montaldi S, Baettig D, Lambert S, Uehlinger C, Kasas A Amey M, Jonzier-Perey M (1996) A doubleblind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: A clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol 16:307-314.
41. Bech P, Rafaelsen OJ (1986) The melancholia scale: development, consistency, validity and utility. In: Sartorius N, Ban TA (eds) Assessment of Depression. Springer, Berlin; Heidelberg, pp 259-269.
42. Bech P, Cialdella P, Haugh MC, Birkett MA Hours A, Boissel JP, Tollefson GD (2000) Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the shortterm treatment of major depression. Br J Psychiatry 176:421-428.
43. Beck AT, Rush AJ, Shaw BF, Emery G (1979) Cognitive therapy of depression. Guilford, New York.
44. Bellack AS, Hersen M (1983) A comparison of social-skills training, pharmacotherapy, and psychotherapy for depression. Behav Res Ther 21:101-107.
45. Benkert O, Hippius H (2000) Kompendium der Psychiatrischen Pharmakotherapie. 2. überarbeitete Auflage. Springer, Berlin, Heidelberg.
46. Berglund M, Nordström G (1984) Mood disorders in alcoholism. Curr Opinion Psychiatry 2:428-433.
47. Berman RM, Narasimhan M, Sanacora G, Miano AP, Hoffman RE, Hu XS, Charney DS, Boutros NN (2000) A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression. Biol Psychiatry 47:332-337.
48. Bertilsson L, Dahl ML, Tybring G (1997) Pharmacogenetics of antidepressants: clinical aspects. Acta Psychiatr Scand 391(Suppl):14-21.
49. Bezchlibnyk-Butler KZ, Jeffries JJ (1996) Clinical Handbook of Psychotropic Drugs. Hogrefe & Huber Publishers, Seattle.
50. Birmaher B, Ryan ND, Williamson DE, Brent DA, Kaufman J, Dahl RE, Perel J, Nelson B (1996) Childhood and adolescent depression: a review of the past 10 years. Part I. J Am Acad Child Adolesc Psychiatry 35:1427-1439.
51. Birmaher B, Brent DA, Benson RS (1998) Summary of the practice parameters for the assessment and treatment of children and adolescents with depressive disorders. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry 37:1234-1238.
52. Blackburn IM, Moore RG (1997) Controlled acute and follow-up trial of cognitive therapy and pharmacotherapy in out-patients with recurrent depression. Br J Psychiatry 171:328-334.
53. Blumenthal JA, Babyak MA, Moore KA, Craighead WE, Herman S, Khatri P, Waugh R, Napolitano MA, Forman LM, Appelbaum M, Doraiswamy PM, Krishnan KR (1999) Effects of exercise training on older patients with major depression. Arch Intern Med 159:2349-2356.
54. Blumenthal SJ (1990) Youth suicide: risk factors, assessment, and treatment of adolescent and young adult suicidal patients. Psychiatr Clin North Am 13:511-556.
55. Boland RJ, Keller MB (2000) Other affective disorders. In: Helmchen H, Henn F, Lauter H, Sartorius N (eds) Contemporary Psychiatry. Vol. 3. Springer, Heidelberg, pp 217-230.
56. Bondareff W, Alpert M, Friedhoff AJ, Richter E, Clary CM Batzar E (2000) Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life. Am J Psychiatry 157:729-736.
57. Booth BM, Zhang M, Rost KM, Clardy JA, Smith LG, Smith GR (1997) Measuring outcomes and costs for major depression. Psychopharmacol Bull 33:653-658.
58. Bostwick JM, Pankratz VS (2000) Affective disorders and suicide risk: a reexamination. Am J Psychiatry 157:1925-1932.
59. Boukoms A, Mangini L (1993) Pergolide: an antidepressant adjuvant for mood disorders? Psychopharmacol Bull 29:207-211.
60. Bourgon LN, Kellner CH (2000) Relapse of depression after ECT: a review. J ECT 16:19-31.
61. Brent DA, Ryan N, Dahl R, Birmaher (1995) Early-onset mood disorder. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: The Fourth Generation of Progress. Raven Press, New York, pp 1631-1642.
62. Brøsen K (1996) Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. Ther Drug Monit 18:393-396.
63. Brøsen K (1998) Differences in interactions of SSRIs. Int Clin Psychopharmacol 13(Suppl 5):S45-S47.
64. Brunello N, Burrows GD, Jönsson CPB, Judd LL, Kasper S, Keller MB, Kupfer DJ, Lecrubier Y, Mendlewicz J, Montgomery SA, Nemeroff CB, Preskom S, Racagni G, Rush AJ (1995) Critical issues in the treatment of affective disorders. Depression 3:187-198.
65. Burrows GD, Norman TR (1999) Treatment-resistant unipolar depression. In: Lader M, Naber D (eds) Difficult Clinical Problems in Psychiatry. Martin Dunitz Ltd, London, pp 57-75.
66. Burt VK, Suri R, Altshuler LL, Stowe ZN, Hendrick V, Muntean E (2001) The use of psychotropic medications during breast-feeding. Am J Psychiatry 158:1001-1009.
67. Byerley WF, Judd LL, Relmherr FW, Grosser BI (1987) 5-Hydroxytryptophan: a review of its antidepressant efficacy and adverse effects. J Clin Psychopharmacol 7:127-137.
68. CANMAT (Canadian Psychiatric Association and the Canadian Network for Mood and Anxiety Treatments) (2000) Clinical Guidelines for the Treatment of Depressive Disorders. Can J Psychiatry 46(Suppl 1):1S-90S.
69. Carpenter LL, Jocic Z, Hall JM, Rasmussen SA, Price LH (1999) Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry 60:45-49.
70. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL (1996) Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 335:1010-1015.
71. Chiba K, Kobayashi K (2000) Antidepressants. In: Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M (eds) Metabolic Drug Interactions. Lippincott Williams & Wilkins, Philadelphia, pp 233-243.
72. Cole MC, Bellavance F, Asmaâ M (1999) Prognosis of depression in elderly community and primary care populations: a systematic review and meta-analysis. Am J Psychiatry 156:1182-1189.
73. Coppen A, Shaw DM, Farrell JP (1963) Potentiation of antidepressive effect of a monoamine-oxidase inhibitor by tryptophan. Lancet 1:79-81.
74. Coppen A, Shaw DM, Herzberg B, Maggs R (1967) Tryptophan in the treatment of depression. 2:1178-1180.
75. Coryell W (2000) Augmentation strategies for inadequate antidepressant response: a review of placebo-controlled studies. Ann Clin Psychiatry 12:141-146.
76. Crismon ML, Trivedi M, Pigott TA, Rush AJ, Hirschfeld RM, Kahn DA, DeBattista C, Nelson JC, Nierenberg AA, Sackeim HA, Thase ME (1999) The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. J Clin Psychiatry 60:142-156.
77. Dam J, Ryde L, Svejso], Lauge N, Lauritsen B, Bech P (1998) Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression. Pharmacopsychiatry 31:48-54.
78. Danish University Antidepressant Group (1986) Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology (Berl) 90:131-138.
79. Danish University Antidepressant Group (1993) Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 28:105-116.
80. Danish University Antidepressant Group (1999) Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 18:289-299.
81. Datto CJ (2000) Side effects of electroconvulsive therapy. Depress Anxiety 12:130-134.
82. Davidson JR (2001) Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 62(Suppl 11):46-50.
83. De Jonghe F, Kool S, van Aalst G, Dekker J, Peen J (2001) Combining psychotherapy and antidepressants in the treatment of depression. J Affect Disord 64:217-229.
84. DeRubeis RJ, Gelfand LA, Tang TZ, Simons AD (1999) Medications versus cognitive behavior therapy for severely depressed outpatients: mega-analysis of four randomized comparisons. Am J Psychiatry 156:1007-1013.
85. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde, DGPPN (2000) Praxisleitlinien in Psychiatrie und Psychotherapie (Gaebel W, Falkai P, Redaktion) Band 5. Behandlungsleitlinie Affektfve Erkrankungen. Steinkopff, Darmstadt.
86. Devanand DP, Dwork AJ, Hutchinson ER, Bolwig TG, Sackeim HA (1994) Does ECT alter brain structure? Am J Psychiatry 151:957-970.
87. Devanand DP, Sano M, Tang MX, Taylor S, Gurland BJ, Wilder D, Stem Y, Mayeux R (1996) Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community. Arch Gen Psychiatry 53:175-182.
88. Dietrich DE, Emrich HM (1998) The use of anticonvulsants to augment antidepressant medication. J Clin Psychiatry 59(Suppl 5):51-58.
89. DiMatteo MR, Lepper HS, Crogan TW (2000) Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 160:2001-2007.
90. Dimeo F, Bauer M, Varahram. I, Proest G, Halter U (2001) Benefits from aerobic exercise in patients with major depression: a pilot study. Brit J Sports Med 35:114-117.
91. Dobson KS (1989) A metaanalysis of the efficacy of cognitive therapy for depression. J Consult Clin Psychol 57:414-419.
92. Duman RS, Heninger GR, Nestler EJ (1997) A molecular and cellular theory of depression. Arch Gen Psychiatry 54:607-608.
93. Duman RS (1998) Novel therapeutic approaches beyond the serotonin receptor. Biol Psychiatry 44:324-335.
94. Dunner DL, Cohn JB, Walshe T 3rd, Cohn CK, Feighner JP, Fieve RR, Halikas JP, Hartford JT, Hearst ED, Settle EC Jr (1992) Two combined, multicenter double-blind studies of paroxetine and doxepine in geriatric patients with major depression. J Clin Psychiatry 53(Suppl):57-60.
95. Eastman CI, Young MA, Fogg LF, Liu L, Meaden PM (1998) Bright light treatment of winter depression: a placebo-controlled trial. Arch Gen Psychiatry 55:883-889.
96. Edwards JG, Anderson I (1999) Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 57:507-533.
97. Einarson TR, Arikian SR, Casciano J, Doyle JJ (1999) Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials. Clin Ther 21:296-308.
98. Elkin I, Shea MT, Watkins JT, Imber SD, Sotsky SM, Collins JF, Glass DR, Pilkonis PA, Leber WR, Docherty JP, Fiester SJ, Parloff MB (1989) NIMH Treatment of Depression Collaborative Research Program: general effectiveness of treatments. Arch Gen Psychiatry 46:971-982.
99. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T, Rintelmann J (1997) A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 54:1031-1037.
100. Enns MW, Swenson JR, Mclntyre RS, Swinson RP, Kennedy SH (2001) Clinical guidelines for the treatment of depressive disorders. VII. Comorbidity. Can J Psychiatry 46(Suppl 1):77S-90S.
101. Entsuah AR, Rudolph RL, Chitra R (1995) Effectiveness of venlafaxine treatment in a broad spectrum of depressed patients: a meta-analysis. Psychopharmacol Bull 31:759-766.
102. Fava GA, Rafanelli C, Grandi S, Conti S, Belluardo P (1998) Prevention of recurrent depression with cognitive behavioral therapy: preliminary findings. Arch Gen Psychiatry 55:816-820.
103. Fava M, Kendler KS (2000) Major depressive disorder. Neuron 28:335-341.
104. Fawcett J, Barton RL (1998) A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. J Clin Psychiatry 59:123-127.
105. Feighner JP (1999) Mechanism of action of antidepressant medications. J Clin Psychiatry 60(Suppl 4):4-11.
106. Ferguson JM (2001) The effects of antidepressants on sexual functioning in depressed patients: a review. J Clin Psychiatry 62(Suppl 3):22-34.
107. Ferreri M, Lavergne F, Berlin I, Payan C, Puech AJ (2001) Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatr Scand 103:66-72.
108. Fink M (2001) Convulsive therapy: a review of the first 55 years. J Affect Disord 63:1-15.
109. Fleming JE, Offord DR (1990) Epidemiology of childhood depressive disorders: a critical review. J Am Acad Child Adolesc Psychiatry 29:571-580.
110. Flint AJ (1998) Choosing appropriate antidepressant therapy in the elderly. A risk-benefit assessment of available agents. Drugs Aging 13:269-280.
111. Flint AJ, Rifat SL (1998) The treatment of psychotic depression in later life: a comparison of pharmacotherapy and ECT. Int J Geriatr Psychiatry 13:23-28.
112. Frank E, Kupfer DJ (1990) Axis II personality disorders and personality features in treatment-resistant and refractory depression. In: Roose SP, Classman AH (eds) Treatment Strategies for Refractory Depression. American Psychiatric Press, Washington DC, pp 207-221.
113. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, Rush AJ, Weissmann MM (1991) Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Arch Gen Psychiatry 48:851-855.
114. Frank E, Thase ME, Spanier C, Cyranowski JM, Siegel L (2000) Psychotherapy of affective disorders. In: Helmchen H, Henn F, Lauter H, Sartorius N (eds) Contemporary Psychiatry. Vol. 3. Springer, Heidelberg, pp 348-363.
115. Furukawa T, Streiner DL, Young LT (2001) Antidepressant plus benzodiazepine for major depression (Cochrane Review). In: The Cochrane Library, Issue 1. Update Software, Oxford.
116. Caffan EA, Tsaousis I, Kemp-Wheeler SM (1995) Researcher allegiance and meta-analysis: the case of cognitive therapy for depression. J Consult Clin Psychol 63:966-980.
117. Gagné GG Jr, Furman MJ, Carpenter LL, Price LH (2000) Efficacy of continuation ECT and antidepressant drugs compared to longterm antidepressants alone in depressed patients. Am J Psychiatry 157:1960-1965.
118. Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J (2001) Selective serotonin reuptake inhibitors (SSRIs) for depression (Cochrane Review). In: The Cochrane Library, Issue 3, Update Software, Oxford.
119. Geller B, Reising D, Leonard HL, Riddle MA, Walsh BT (1999) Critical review of tricyclic antidepressant use in children and adolescents. J Am Acad Child Adolesc Psychiatry 38:513-516.
120. George MS, Wassermann EM, Kimbrell TA, Little JT, Williams WE, Danielson AL, Greenberg BD, Hallett M, Post RM (1997) Mood improvement following daily left prefrontal repetitive transcranial magnetic stimulation in patients with depression: a placebocontrolled crossover trial. Am J Psychiatry 154:1752-1756.
121. George MS, Lisanby SH, Sackeim HA (1999) Transcranial magnetic stimulation: applications in neuropsychiatry. Arch Gen Psychiatry 56:300-311.
122. George MS, Sackeim HA, Rush AJ, Marangell LB, Nahas Z, Husain MM, Lisanby S, Burt T, Goldman J, Ballenger JC (2000) Vagus nerve stimulation: a new tool for brain research and therapy. Biol Psychiatry 47:287-295.
123. Gerson S, Belin TR, Kaufman A, Mintz J, Jarvik L (1999) Pharmacological and psychological treatments for depressed older patients: a meta-analysis and overview of recent findings. Harv Rev Psychiatry 7:1-28.
124. Gilbert DA, Altshuler KZ, Rago WV, Shon SP, Crismon ML, Toprac MG, Rush AJ (1998) Texas medication algorithm project: definitions, rationale, and methods to develop medication algorithms. J Clin Psychiatry 59:345-351.
125. Gill D, Hatcher S (2001) Antidepressants for depression in people with physical illness (Cochrane Review). In: The Cochrane Library, Issue 1. Update Software, Oxford.
126. Glassman AH, Platman SR (1969) Potentiation of a monoamine oxidase inhibitor by tryptophan. J Psychiatr Res 7:83-88.
127. Glogauen V, Cottraux J, Cucherat M, Blackburn IM (1998) A metaanalysis of the effects of cognitive therapy in depressed patients. J Affect Disord 49:59-72.
128. Goodnick PJ, Jorge CA, Hunter T, Kumar AM (2000) Nefazodone treatment of adolescent depression: an open-label study of response and biochemistry. Ann Clin Psychiatry 12:97-100.
129. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER (1993) The economic burden of depression in 1990. J Clin Psychiatry 54:405-418.
130. Guscott R, Grof P (1991) The clinical meaning of refractory depression: a review for the clinician. Am J Psychiatry 148:695-704.
131. Guy W (1976) ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. National Institute of Mental Health, Rockville, MD, pp 218-222.
132. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
133. Harrington R, Whittaker J, Shoebridge P (1998) Psychological treatment of depression in children and adolescents. A review of treatment research. Br J Psychiatry 173:291-298.
134. Hawley CJ, Pattinson HA, Quick SJ, Echlin D, Smith V, McPhee S, Sivakumaran T (1998) A protocol for the pharmacologic treatment of major depression. A field test of a potential prototype. J Affect Disord 47:87-96.
135. Hazell P, O'Connell D, Heathcote D, Henry D (2001) Tricyclics in child and adolescent depression (Cochrane Review). In: The Cochrane Library, Issue 3. Update Software, Oxford.
136. Hendrick V, Fukuchi A, Altshuler LL, Widawsky M, Wertheimer A, Brunhuber M (2001) Use of sertraline, paroxetine and fluvoxamine by nursing women. Br J Psychiatry 179:163-166.
137. Hiemke C, Härtter S (2000) Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 85:11-28.
138. Hirschfeld RM, Montgomery SA, Keller MB, Kasper S, Schatzberg AF, Möller HJ, Healy D, Baldwin D, Humble M, Versiani M, Montenegro R, Bourgeois M (2000) Social functioning in depression: a review. J Clin Psychiatry 61:268-275.
139. Hirschfeld RM (2001) Clinical importance of Ion-term antidepressant treatment. Br J Psychiatry 179(Suppl 42):s4-s8.
140. Hoffbrand S, Howard L, Crawley H (2001) Antidepressant treatment for post-natal depression (Cochrane Review). In: The Cochrane Library, Issue 3. Update Software, Oxford.
141. Hollon SD, DeRubeis RJ, Evans MD, Wiener MJ, Garvey MJ, Grove WM, Tuason VB (1992) Cognitive therapy and pharmacotherapy for depression. Arch Gen Psychiatry 49:774-781.
142. Holsboer F (2000) The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23:477-501.
143. Holsboer F (2001) Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy. J Affect Disord 62:77-91.
144. Hotopf M, Hardy R, Lewis G (1997) Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. Br J Psychiatry 170:120-127.
145. Inoue T, Tsuchiya K, Miura J, Sakakibara S, Denda K, Kasahara T, Koyama T (1996) Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression. Biol Psychiatry 40:151-153.
146. larrett RB, Rush AJ (1994) Short term psychotherapy of depressive disorders: current status and future directions. Psychiatry 57:115-132.
147. Jarrett RB, Kraft D, Doyle J, Foster BM, Eaves GG, Silver PC (2001) Preventing recurrent depression using cognitive therapy with and without a continuation phase: a randomized clinical trial. Arch Gen Psychiatry 58:381-388.
148. Joffe RT, Singer W, Levitt AJ, MacDonald C (1993) A placebocontrolled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 50:387-393.
149. Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, Paulus MP, Kunovac JL, Leon AC, Mueller TI, Rice JA Keller MB (1998) A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 55:694-700.
150. judd LL, Akiskal HS, Zeller PJ, Paulus M, Leon AC, Maser JD, Endicott J, Coryell W, Kunovac JL, Mueller TI, Rice JP, Keller MB (2000a) Psychosocial disability during the long-term course of unipolar major depressive disorder. Arch Gen Psychiatry 57:375-380.
151. Judd LL, Paulus MJ, Schettler PJ, Akiskal HS, Endicott J, Leon AC, Maser JD, Mueller T, Solomon DA, Keller MB (2000b) Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry 157:1501-1504.
152. Karlsson I, Codderis J, Augusto De Mendonca Lima C, Nygaard H, Simanyi M, Taal M, Eglin M (2000) A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia. Int J Geriatr Psychiatry 15:295-305.
153. Kasper S (1997) Efficacy of antidepressants in the treatment of severe depression: the place of mirtazapine. J Clin Psychopharmacol 17(Suppl 1):19S-28S.
154. Kasper S, Wehr TA, Bartko JJ, Caist PA, Rosenthal NE (1989) Epidemiological findings of seasonal changes in mood and behavior. A telephone survey of Montgomery County, Maryland. Arch Gen Psychiatry 46:823-833.
155. Katon W, Von Korff M, Lin E, Walker E, Simon GE, Bush T, Robinson P, Russo J (1995) Collaborative management to achieve treatment guidelines. Impact on depression in primary care. JAMA 273:1026-1031.
156. Katona CL (2000) Managing depression and anxiety in the elderly patient. Eur Neuropsychopharmacol 10(Suppl 4):S427-S432.
157. Katona CL, Finch EJL (1991) Lithium augmentation for refractory depression in old age. In: Amsterdam JD (ed) Advances in Neuropsychiatry and Psychopharmacology, Vol 2: Refractory Depression. Raven Press, New York, pp 177-184.
158. Katona CL, Abou-Saleh MT, Harrison DA, Nairac BA, Edwards DRL, Lock T, Bums RA, Robertson MM (1995) Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 166:80-86.
159. Katona CL, Hunter BN, Bray J (1998) A double-blind comparison of the efficacy and safely of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry 13:100-108.
160. Katona CL, Bercoff E, Chiu E, Tack P, Versiani M, Woelk H (1999) Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial. J Affect Disord 55:203-213.
161. Keller MB, Lavori PW, Rice J, Coryell W, Hirschfeld RMA (1986) The persistent risk of chronicity in recurrent episodes of nonbipolar major depressive disorder a prospective follow-up. Am J Psychiatry 143:24-28.
162. Keller MB, McCullough JP, Klein DN, Amow B, Dunner DL, Gelenberg AJ, Markowitz JC, Nemeroff CB, Russell JM, Thase ME, Trivedi MH, Zajecka J (2000) A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 342:1462-1470.
163. Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B, Hagino OR, Koplewicz H, Carlson GA, Clarke GN, Emslie GJ, Feinberg D, Celler B, Kusumakar V, Papatheodorou G, Sack WH, Sweeney M, Wagner KD, Weller EB, Winters NC, Oakes R, McCafferty JP (2001) Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 40:762-772.
164. Kennedy SH, Lam RW, Cohen NL, Ravindran AV, and the CANMAT Depression Work Group (2001) Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry 46(Suppl 1):38S-58S.
165. Kent JM (2000) SNaRls, NaSSAs, and NaRls: new agents for the treatment of depression. Lancet 355:911-918.
166. Kessler RC, McGonagle KA Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 51:8-19.
167. Kessler RC, Avenevoli S, Ries Merikangas K (2001) Mood disorders in children and adolescents: an epidemiologic perspective. Biol Psychiatry 49:1002-1014.
168. Khan A, Warner HA, Brown WA (2000) Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry 57:311-317.
169. Kim HL, Streltzer J, Goebert D (1999) St John's wort for depression: a meta-analysis of well-defined clinical trials. J Nerv Ment Dis 187:532-538.
170. Klein E, Kreinin I, Chistyakov A, Koren D, Mecz L, Marmur S, Ben-Shachar D, Feinsod M (1999) Therapeutic efficacy of right prefrontal slow repetitive transcranial magnetic stimulation in major depression: a double-blind controlled study. Arch Gen Psychiatry 56:315-320.
171. Klerman GL, Weissmann MM, Rounsaville BJ, Chevron ES (1984) Interpersonal psychotherapy of depression. Basic Books, New York.
172. Klerman GL, Weissman MM (1992) The course, morbidity, and costs of depression. Arch Gen Psychiatry 49:831-834.
173. Koran LM, Gelenberg AJ, Kornstein SG, Howland RH, Friedman RA, DeBattista C, Klein D, Kocsis JH, Schatzberg AF, Thase ME, Rush AJ, Hirschfeld RM, LaVange LM, Keller MB (2001) Sertraline versus imipramine to prevent relapse in chronic depression. J Affect Disord 65:27-36.
174. Kovacs M (1996) Presentation and course of major depressive disorder during childhood and later years of the life span. J Am Acad Child Adolesc Psychiatry 35:705-715.
175. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt-Knowles E, Hale JJ, Mills SG, MacCoss M, Swain CJ, Harrison T, Hill RG, Hefti F, Scolnick EM, Cascìerì MA Chicchi GG, Sadowski S, Williams AR, Hewson L, Smith D, Carlson EJ, Hargreaves RJ, Rupniak NMJ (1998) Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281:1640-1645.
176. Kuhs H, Tölle R (1991) Sleep deprivation therapy. Biol Psychiatry 29:1129-1148.
177. Kuhs H, Farber D, Borgstadt S, Mrosek S, Tolle R (1996) Amitriptytine in combination with repeated late sleep deprivation versus amitriptyline alone in major depression. A randomised study. J Affect Disord 37:31-41.
178. Kupfer DJ (1993) Managment of recurrent depression. J Clin Psychiatry 54(Suppl 2):29-33.
179. Kushnir SL (1986) Lithium-antidepressant combinations in the treatment of depressed, physically ill geriatric patients. Am J Psychiatry 143:378-379.
180. Lam RW, Gorman CP, Michalon M, Steiner M, Levitt AJ, Corral MR, Watson GD, Morehouse RL, Tarn W, Joffe RT (1995) Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder. Am J Psychiatry 152:1765-1770.
181. Lam RW, Levitt AJ (1999) (eds) Canadian Consensus Guidelines for the Treatment of Seasonal Affective Disorder. Clinical & Academic Publishing, Vancouver, BC, Canada.
182. Landén M, Björling G, Ågren H, Fahlén T (1998) A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry 59:664-668.
183. Lauritzen L, Odgaard K, Clemmesen L, Lunde M, Ohrstrom J, Black C, Bech P (1996) Relapse prevention by means of paroxetine in ECT-treated patients with major depression: a comparison with imipramine and placebo in medium-term continuation therapy. Acta Psychiatr Scand 94:241-251.
184. Lawlor DA, Hopker SW (2001) The effectiveness of exercise as an intervention in the management of depression: systematic review and meta-regression analysis of randomised controlled trials. BMJ 322:763-767.
185. Lee TM, Chan CC (1999) Dose-response relationship of phototherapy for seasonal affective disorder: a meta-analysis. Acta Psychiatr Scand 99:315-323.
186. Leonard BE (1995) Mechanisms of action of antidepressants. CNS Drugs 4(Suppl 1):1-12.
187. Leonard HL, March J, Rickler KC, Allen AJ (1997) Pharmacology of the selective serotonin reuptake inhibitors in children and adolescents. J Am Acad Child Adolesc Psychiatry 36:725-736.
188. Lewinsohn PM, Clarke G (1984) Group treatment of depressed individuals. The coping with depression course. Advances in Behavioral Research and Therapy 6:99-114.
189. Lewy AJ, Bauer VK, Cutler NL, Sack RL, Ahmed S, Thomas KH, Blood ML, Jackson JM (1998) Morning vs evening light treatment of patients with winter depression. Arch Gen Psychiatry 55:890-896.
190. Linde K, Mulrow CD (2001) St. John's wort for depression (Cochrane Review). In: The Cochrane Library, 1. Update Software, Oxford.
191. Lipsey JR, Robinson RG, Pearlson GD, Rao K, Price TR (1984) Nortriptyline treatment of post-stroke depression: a double-blind study. Lancet 1:297-300.
192. Loo C, Mitchell P, Sachdev P, McDarmont B, Parker G, Gandevia S (1999) Double-blind controlled investigation of transcranial magnetic stimulation for the treatment of resistant major depression. Am J Psychiatry 156:946-948.
193. Lotufo-Neto F, Trivedi M, Thase ME (1999) Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology 20:226-247.
194. *35 allele in ultrarapid metabolism? Pharmacogenetics 11:2001-2007.
195. Lundmark J, Bengtsson F, Nordin C, Reis M, Walinder J (2000) Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiatr Scand 101:354-359.
196. Lyketsos CG, Sheppard JM, Steele CD, Kopunek S, Steinberg M, Baker AS, Brandt J, Rabins PV (2000) Randomized, placebocontrolled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the Depression in Alzheimer's Disease study. Am J Psychiatry 157:1686-1689.
197. Mace S, Taylor D (2000) Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression. Expert Opin Pharmacother 1:917-933.
198. Maes M, Vandoolaeghe E, Desnyder R (1996) Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J Affect Disord 41:201-210.
199. Maier W, Schwab S, Rietschel M (2000) Genetics of Affective Disorders. In: Helmchen H, Henn F, Lauter H, Sartorius N (eds) Contemporary Psychiatry. Vol. 3. Springer, Heidelberg, pp 243-266.
200. Mandoki MW, Tapia MR, Tapia MA, Sumner GS, Parker JL (1997) Venlafaxine in the treatment of children and adolescents with major depression. Psychopharmacol Bull 33:149-154.
201. Manly DT, Oakley SP Jr, Bloch RM (2000) Electroconvulsive therapy in old-old patients. Am J Geriatr Psychiatry 8:232-236.
202. Maubach KA, Rupniak NM, Kramer MS, Hill RG (1999) Novel strategies for pharmacotherapy of depression. Curr Opin Chem Biol 3:481-488.
203. McCullough JP (2000) Treatment for Chronic Depression: Cognitive Behavioral Analysis System of Psychotherapy. Guilford Press, New York.
204. McCusker J, Cole M, Keller E, Bellavance F, Berard A (1998) Effectiveness of treatments of depression in older ambulatory patients. Arch Intern Med 158:705-712.
205. McNamara B, Ray JL, Arthurs J, Boniface S (2001) Transcranial magnetic stimulation for depression and other psychiatric disorders. Psychol Med 31:1141-1146.
206. Mendels J, Stinnett JL, Burns D, Frazer A (1975) Amine precursors and depression. Arch Gen Psychiatry 32:22-30.
207. Michalets EL (1998) Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 18:84-112.
208. Mintz J, Mintz LI, Arruda MJ, Hwang SS (1992) Treatments of depression and functional capacity to work. Arch Gen Psychiatry 49:761-768.
209. Mittmann N, Herrmann N, Einarson TR, Busto UE, Lanctot KL, Liu BA, Shulman KI, Silver IL, Narango CA, Shear NH (1997) The efficacy, safety and tolerability of antidepressants in late life depression: a meta-analysis. J Affect Disord 46:191-217.
210. Möller HJ (1994) Non-response to antidepressants: risk factors and therapeutic possibilities. Int Clin Psychopharmacol 9(Suppl 2):17-23.
211. Möller HJ (2000) Are all antidepressants the same? J Clin Psychiatry 61(Suppl 6):24-28.
212. Möller HJ, Fuger J, Kasper S (1994) Efficacy of new generation antidepressants: meta-analysis of imipramine-controlled studies. Pharmacopsychiatry 27:215-223.
213. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F (2001) Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 62(Suppl 3):10-21.
214. Montgomery SA, Åsberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
215. Montgomery SA (1991) Selectivity of antidepressants and resistant depression. In: Amsterdam JD (ed) Advances in Neuropsychiatry and Psychopharmacology, Vol 2: Refractory Depression. Raven Press, New York, pp 93-104.
216. Montgomery SA (1999) New developments in the treatment of depression. J Clin Psychiatry 60(Suppl 14):10-15.
217. Mueller Tl, Leon AC, Keller MB, Solomon DA, Endicott J, Coryell W, Warshaw M, Maser JD (1999) Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry 156:1000-1006.
218. Mulsant BH, Pollock BG (1998) Treatment-resistant depression in late life. J Geriatr Psychiatry Neurol 11:186-193.
219. Mulsant BH, Pollock BG, Nebes RD, Miller MD, Little JT, Stack J, Houck PR, Bensasi S, Mazumdar S, Reynolds CF 3rd (1999) A double-blind randomized comparison of nortriptyline and paroxetine in the treatment of late-life depression: 6-week outcome. J Clin Psychiatry 60(Suppl 20):16-20.
220. Murphy BE (1997) Antiglucocorticoid therapies in major depression: a review. Psychoneuroendocrinology 22(Suppl 1):S12S-S132.
221. Murray CJL, Lopez AD (1997a) Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 349:1436-1342.
222. Murray CJL, Lopez AD (1997b) Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349:1498-1504.
223. Mynors-Wallis LM, Gath DH, Day A, Baker F (2000) Randomised controlled trial of problem solving treatment, antidepressant medication, and combined treatment for major depression in primary care. BMJ 320:26-30.
224. Nelson JC (1998) Treatment of antidepressant nonresponders: augmentation or switch? J Clin Psychiatry 59(Suppl 15):35-41.
225. Nelson J, Chouinard G (1999) Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology. Can J Clin Pharmacol 6:69-83.
226. Nemeroff CB (1996-97) Augmentation strategies in patients with refractory depression. Depress Anxiety 4:169-181.
227. Nemeroff CB (1998) Psychopharmacology of affective disorders in the 21st century. Biol Psychiatry 44:517-525.
228. Nemeroff CB, Widerlov E, Bissette G, Walleus H, Karisson I, Eklund K, Kilts CD, Loosen PT, Vale W (1984) Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 226:1342-1344.
229. Nestler EJ (1998) Antidepressant treatments in the 21st century. Biol Psychiatry 44:526-533.
230. Newhouse PA Krishnan KR, Doraiswamy PM, Richter EM, Batzar ED, Clary CM (2000) A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. J Clin Psychiatry 61:559-568.
231. Nezu AM (1986) Efficacy of social problem solving therapy for unipolar depression. J Consult Clin Psychol 54:196-202.
232. Nierenberg AA, Amsterdam JD (1990) Treatment-resistant depression: definition and treatment approaches. J Clin Psychiatry 51(Suppl 6):39-47.
233. Nierenberg AA, McLean NE, Alpert JE, Worthington JJ, Rosenbaum JF, Fava M (1995) Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry 152:1500-1503.
234. Nierenberg AA, Alpert JE, Pava J, Rosenbaum JF, Fava M (1998a) Course and treatment of atypical depression. J Clin Psychiatry 59(Suppl 18):5-9.
235. Nierenberg AA, Dougherty D, Rosenbaum JF (1998b) Dopaminergic agents and stimulants as antidepressant augmentation strategies. J Clin Psychiatry 59(Suppl 5):60-63.
236. Nobler MS, Sackeim HA (2000) Electroconvulsive therapy. In: Helmchen H, Henn F, Lauter H, Sartorius N (eds) Contemporary Psychiatry. Vol. 3. Springer, Heidelberg, pp 425-434.
237. Nolen WA, Zohar J, Roose SP, Amsterdam JD (eds) (1994) Refractory Depression: Current Strategies and Future Directions. J. Wiley & Sons, Chichester.
238. Nordstrom P, Asberg M, Aberg-Wistedt A, Nordin C (1995a) Attempted suicide predicts suicide risk in mood disorders. Acta Psychiatr Scand 92:345-350.
239. Nordstrom P, Samuelsson M, Asberg M (1995b) Survival analysis of suicide risk after attempted suicide. Acta Psychiatr Scand 91:336-340.
240. Nulman I, Koren G (1996) The safety of fluoxetine during pregnancy and lactation. Teratology 53:304-308.
241. Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA Theis JG, Kulin N, Koren G (1997) Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 336:258-262.
242. Nyth AL, Gottfries CG, Lyby K, Smedegaard-Andersen L, Gylding-Sabroe J, Kristensen M, Refsum HE, Ofsti E, Eriksson S, Syversen S (1992) A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 86:138-145.
243. Old Age Depression Interest Group (1993) How long should the elderly take antidepressants? A double-blind placebo-controlled study of continuation/prophylaxis therapy with dothiepin. Br J Psychiatry 162:175-182.
244. Ostroff RB, Nelson JC (1999) Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 60:256-259.
245. Owens MJ, Nemeroff CB (1999) Corticotropin-releasing factor antagonists in affective disorders. Expert Opin Investig Drugs 8:1849-1858.
246. Pascual-Leone A, Rubio B, Pallardo F, Catala MD (1996) Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. Lancet 348:233-237.
247. Paykel ES (1994) Epidemiology of refractory depression. In: Nolen WA, Zohar J, Roose SP, Amsterdam JD (eds) Refractory Depression: Current Strategies and Future Directions, J Wiley & Sons, Chichester, pp 3-17.
248. Paykel ES, Hollyman JA, Freeling P, Sedgwick P (1988) Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo-controlled trial. J Affect Disord 14:83-95.
249. Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A (1995) Residual symptoms after partial remission: an important outcome in depression. Psychol Med 25:1171-1180.
250. Paykel ES, Scott J, Teasdale JD, Johnson AL, Garland A, Moore R, jenaway A, Cornwall PL, Hayhurst H, Abbott R, Pope M (1999) Prevention of relapse in residual depression by cognitive therapy. Arch Gen Psychiatry 56:829-835.
251. Peretti S, Judge R, Hindmarch I (2000) Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand 403(Suppl 2000):17-25.
252. Perez V, Soler J, Puigdemont D, Alvarez E, Artigas F (1999) A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastoms Afectius. Arch Gen Psychiatry 56:375-379.
253. Perez-Stable EJ, Miranda J, Munoz R, Ying Y (1990) Depression in medical outpatients: underrecognition and misdiagnosis. Arch Int Med 150:1083-1088.
254. Perry PJ (1996) Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. J Affect Disord 39:1-6.
255. Perry PJ, Zeilmann C, Arndt S (1994) Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacol 14:230-240.
256. Petracca G, Teson A, Chemerinski E, Leiguarda R, Starkstein SE (1996) A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. J Neuropsychiatry Clin Neurosci 8:270-275.
257. Picinelli M, Gomez Homen F (1997) Gender differences in the epidemiology of affective disorders and schizophrenia. World Health Organization, Geneva, Switzerland.
258. Pigott TA, Seay SM (1999) A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 60:101-106.
259. Pollock BG, Mulsant BH, Nebes R, Kirshner MA, Begley AE, Mazumdar S, Reynolds CF 3rd (1998) Serum anticholinergicity in elderly depressed patients treated with paroxetine or nortriptyline. Am J Psychiatry 155:1110-1112.
260. Potter WZ, Schmidt ME (1997) Treatment of major depression: selection of initial drug. In: Rush AJ (ed) Mood Disorders. Systematic Medication Management. Mod Probl Pharmacopsychiatry 25:1-16.
261. Preskorn SH (1993) Recent pharmacologic advances in antidepressant therapy for the elderly. Am J Med 94(Suppl 5A):2S-12S.
262. Preskorn SH, Fast GA (1991) Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. J Clin Psychiatry 52(Suppl):23-33.
263. Prien RF (1990) Efficacy of continuation drug therapy of depression and anxiety: issues and methodologies. J Clin Psychopharmacol 10:86S-90S.
264. Prien RF, Kupfer DJ (1986) Continuation drug therapy for major depressive episodes: How long should it be maintained? Am J Psychiatry 143:18-23.
265. Quitkin FM, Harrison W, Stewart JW, McGrath PJ, Tricamo E, Ocepek-Welikson K, Rabkin JG, Wager SG, Nunes E, Klein DF (1991) Response to phenelzine and imipramine in placebo nonresponders with atypical depression. A new application of the crossover design. Arch Gen Psychiatry 48:319-323.
266. Rasmussen BB, Brøsen K (2000) Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit 22:143-154.
267. Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK (1993) The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 50:85-94.
268. Rehm LP (1979) Behavior Therapy for Depression. Academic Press, New York.
269. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH (2000) QTcinterval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 355:1048-1052.
270. Reimherr FW, Amsterdam JD, Quitkin FM, Rosenbaum JF, Fava M, Zajecka J, Beasley CM Jr, Michelson D, Roback P, Sundell K (1998) Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am J Psychiatry 155:1247-1253.
271. Reynolds CF 3rd, Frank E, Kupfer DJ, Thase ME, Perel JM, Mazumdar S, Houck PR (1996) Treatment outcome in recurrent major depression: a post hoc comparison of elderly ("young old") and midlife patients. Am J Psychiatry 153:1288-1292.
272. Reynolds CF 3rd, Alexopoulos GS, Katz IR, Lebowitz BD (2001) Chronic depression in the elderly: approaches for prevention. Drugs Aging 18:507-514.
273. Richelson E (1994) The pharmacology of antidepressants at the synapse: focus on newer compounds. J Clin Psychiatry 55(Suppl A):34-39.
274. Richelson E (2001) Pharmacology of antidepressants. Mayo Clin Proc 76:511-527.
275. Riemann D, Konig A, Hohagen F, Kiemen A, Voderholzer U, Backhaus J, Bunz J, Wesiack B, Hermle L, Berger M (1999) How to preserve the antidepressive effect of sleep deprivation: A comparison of sleep phase advance and sleep phase delay. Eur Arch Psychiatry Clin Neurosci 249:231-237.
276. Robinson RG, Schultz SK, Castillo C, Kopel T, Kosier JT, Newman RM, Curdue K, Petracca G, Starkstein SE (2000) Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry 157:351-359.
277. Roose SP, Suthers KM (1998) Antidepressant response in late-life depression. J Clin Psychiatry 59(Suppl 10):4-8.
278. Roose SP, Laghrissi-Thode F, Kennedy JS, Nelson JC, Bigger JT Jr, Pollock BG, Gaffney A, Narayan M, Finkel MS, McCafferty J, Gergel I (1998) Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 279:287-291.
279. Rosen LN, Targum SD, Terman M, Bryant MJ, Hoffman H, Kasper SF, Hamovit JR, Docherty JP, Welch B, Rosenthal NE (1990) Prevalence of seasonal affective disorder at four latitudes. Psychiatry Res 31:131-144.
280. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB (1998) Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 44:77-87.
281. Rosenthal NE, Sack DA, Gillin JC, Lewy AJ, Goodwin FK, Davenport Y, Mueller PS, Newsome DA, Wehr TA (1984) Seasonal affective disorder. A description of the syndrome and preliminary findings with light therapy. Arch Gen Psychiatry 41:72-80.
282. Rothschild AJ, Samson JA, Bessette MP, Carter-Campbell JT (1993) Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. J Clin Psychiatry 54:338-342.
283. Roy A, Dejong J, Lamparski D, George T, Linnoila M (1991) Depression among alcoholics. Relationship to clinical and cerebrospinal fluid variables. Arch Gen Psychiatry 48:428-432.
284. Rudolph RL, Entsuah R, Chitra R (1998) A meta-analysis of the effects of venlafaxine on anxiety associated with depression. J Clin Psychopharmacol 18:136-144.
285. Ruhrmann S, Kasper S, Hawellek B, Martinez B, Hoflich G, Nickelsen T, Moller HJ (1998) Effects of fluoxetine versus bright light in the treatment of seasonal affective disorder. Psychol Med 28:923-933.
286. Rush AJ, Crismon ML, Toprac MG, Trivedi MH, Rago WV, Shon SP, Altshuler KZ (1998) Consensus guidelines in the treatment of major depressive disorder. J Clin Psychiatry 59(Suppl 20):73-84.
287. Rush AJ, Kupfer DJ (2001) Strategies and tactics in the treatment of depression. In: Gabbard GO (ed) Treatment of Psychiatric Disorders. Third Edition. American Psychiatric Publishing Inc, Washington, DC, pp 1417-1439.
288. Rush AJ, Thase ME (1999) Psychotherapies for depressive disorders. In: Maj M, Sartorius N (eds) WPA Series. Evidence and Experience in Psychiatry. Volume 1 - Depressive Disorders. John Wiley & Sons Ltd, Chichester, UK, pp 161-206.
289. Rush AJ, Rago WV, Crismon ML, Toprac MG, Shon SP, Suppes T, Miller AL, Trivedi MH, Swann AC, Biggs MM, Shores-Wilson K, Kashner TM, Pigott T, Chiles JA, Gilbert DA, Altshuler KZ (1999) Medication treatment for the severely and persistently ill: the Texas medication algorithm project. J Clin Psychiatry 60:284-291.
290. Rush AJ, George MS, Sackeim HA, Marangell LB, Husain MM, Ciller C, Nahas Z, Haines S, Simpson RK Jr, Goodman R (2000) Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol Psychiatry 47:276-286.
291. Sackeim HA, Decina P, Portnoy S, Neeley P, Malitz S (1987) Studies of dosage, seizure threshold, and seizure duration in ECT. Biol Psychiatry 22:249-68.
292. Sackeim HA, Prudic J, Devanand DP, Kiersky JE, Fitzsimons L, Moody BJ, McElhiney MC, Coleman EA, Settembrino JM (1993) Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. N Engl J Med 328:839-846.
293. Sackeim HA, Haskett RF, Mulsant BH, Thase ME, Mann JJ, Pettinati HM, Greenberg RM, Crowe RR, Cooper TB, Prudic J (2001) Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA 285:1299-1307.
294. Schatzberg AF (2000) New indications for antidepressants. J Clin Psychiatry 61(Suppl 11):9-17.
295. Schuckit MA (1994) Alcohol and depression: a clinical perspective. Acta Psychiatr Scand 377(Suppl):28-32.
296. Schulberg HC, Block MR; Madonia MJ, Scott CP, Rodriguez E, Imber SD, Perel J, Lave J, Houck PR, Coulehan JL (1996) Treating major depression in primary care practice: eight month clinical outcomes. Arch Gen Psychiatry 53:913-919.
297. Scott J (1988) Chronic depression. Br J Psychiatry 153:287-297.
298. Scott J, Cilvarry E, Farrell M (1998) Managing anxiety and depression in alcohol and drug dependence. Addict Behav 23:919-931.
299. Scott J, Teasdale JD, Paykel ES, Johnson AL, Abbott R, Hayhurst H, Moore R, Garland A (2000) Effects of cognitive therapy on psychological symptoms and social functioning in residual depression. Br J Psychiatry 177:440-446.
300. Segal ZV, Kennedy SH, Cohen NL and the CANMAT Depression Work Group (2001) Clinical guidelines for the treatment of depressive disorders. V. Combining psychotherapy and pharmacotherapy. Can J Psychiatry 46(Suppl 1):59S-62S.
301. Shaw K, Turner J, Del Mar. C (2001) Tryptophan and 5-Hydroxytryptophan for Depression (Cochrane Review). In: The Cochrane Library, Issue 3. Update Software, Oxford.
302. Shekelle PC, Woolf SH, Eccles M, Grimshaw J (1999) Developing guidelines. BMJ 318:593-596.
303. Shelton RC, Keller MB, Gelenberg A, Dunner DL, Hirschfeld R, Thase ME, Russell J, Lydiard RB, Crits-Cristoph P, Gallop R, Todd L, Hellerstein D, Goodnick P, Keitner G, Stahl SM, Halbreich U (2001a) Effectiveness of St. John's Wort in major depression. A randomized controlled trial. JAMA 285:1978-1986.
304. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, Feldman PD, Meltzer HY (2001b) A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 158:131-134.
305. Sherwin BB (1991) Estrogen and refractory depression. In: Amsterdam JD (ed) Advances in Neuropsychiatry and Psychopharmacology, Vol 2: Refractory Depression. Raven Press, New York, pp 209-218.
306. Shores MM, Pascualy M, Veith RC (1998) Depression and Heart Disease: Treatment Trials. Semin Clin Neuropsychiatry 3:87-101.
307. Simon GE, VonKorff M, Heiligenstein JH, Revicki DA, Grothaus L, Katon W, Wagner EH (1996) Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine versus tricyclic antidepressants. JAMA 275:1897-1902.
308. Solomon DA Keller MB, Leon AC, Mueller TI, Shea MT, Warshaw M, Maser JD, Coryell W, Endicott J (1997) Recovery from major depression. A 10-year prospective follow-up across multiple episodes. Arch Gen Psychiatry 54:1001-1006.
309. Spiker DG, Weiss JC, Dealy RS, Griffin SJ, Hanin I, Neil JF, Perel JM, Rossi AJ, Soloff PH (1985) The pharmacological treatment of delusional depression. Am J Psychiatry 142:430-436.
310. Sproule BA, Hardy BG, Shulman KI (2000) Differential pharmacokinetics of lithium in elderly patients. Drugs Aging 16:165-177.
311. Staab JP, Evans DL (2000) Efficacy of venlafaxine in geriatric depression. Depress Anxiety 12(Suppl 1):63-68.
312. Stahl SM (2000) Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biol Psychiatry 48:894-901.
313. Steffens DC, Skoog I, Norton MC, Hart AD, Tschanz JT, Plassman BL, Wyse BW, Welsh-Bohmer KA, Breitner JC (2000) Prevalence of depression and its treatment in an elderly population: the Cache County study. Arch Gen Psychiatry 57:601-607.
314. Steimer W, Muller B, Leucht S, Kissling W (2001) Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy. Clin Chim Acta 308:33-41.
315. Sternbach H (1995) The serotonin syndrome. Am J Psychiatry 148:705-713.
316. Storosum JG, Elferink AJ, van Zwieten BJ, van den Brink W, Gersons BP, van Strik R, Broekmans AW (2001) Short-term efficacy of tricyclic antidepressants revisited: a meta-analytic study. Eur Neuropsychopharmacol 11:173-180.
317. Stowe ZN, Cohen LS, Hostetter A, Ritchie JC, Owens MJ, Nemeroff CB (2000) Paroxetine in human breast milk and nursing infants. Am J Psychiatry 157:185-189.
318. Sullivan PF, Neale MC, Kendler KS (2000) Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry 157:1552-1562.
319. Tanaka E, Hisawa S (1999) Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system. J Clin Pharm Ther 24:7-16.
320. Taragano FE, Lyketsos CG, Mangone CA, Allegri RF, Comesana-Diaz E (1997) A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics 38:246-252.
321. Ten L, Reifler BV, Veith RC, Barnes R, White E, McLean P, Raskind M (1991) Imipramine in the treatment of depressed Alzheimer's patients: impact on cognition. J Gerontol 46: P372-P377.
322. Terman M, Terman JS, Ross DC (1998) A controlled trial of timed bright light and negative air ionization for treatment of winter depression. Arch Gen Psychiatry 55:875-882.
323. Tew JD Jr, Mulsant BH, Haskett RF, Prudic J, Thase ME, Crowe RR, Dolata D, Begley AE, Reynolds CF 3rd, Sackeim HA (1999) Acute efficacy of ECT in the treatment of major depression in the old-old. Am J Psychiatry 156:1865-1870.
324. Thase ME (1990) Relapse and recurrence in unipolar major depression: short-term and long-term approaches. J Clin Psychiatry 51(Suppl 6):51-57.
325. Thase ME (1999) Redefining antidepressant efficacy toward longterm recovery. J Clin Psychiatry 60(Suppl 6):15-19.
326. Thase ME, Howland RH (1994) Refractory depression: relevance of psychosocial factors and therapies. Psychiatr Ann 24:232-240.
327. Thase ME, Rush AJ (1995) Treatment-resistant depression. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: The Fourth Generation of Progress. Raven Press, New York, pp 1081-1097.
328. Thase ME, Rush AJ (1997) When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 58(Suppl 13):23-29.
329. Thase ME, Trivedi MH, Rush AJ (1995) MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 12:185-219.
330. Thase ME, Greenhouse JB, Frank E, Reynolds CF 3rd, Pilkonis PA, Hurley K, Grochocinski V, Kupfer DJ (1997) Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry 54:1009-1015.
331. Thase ME, Howland RH, Friedman ES (1998) Treating antidepressant nonresponders with augmentation strategies: an overview. J Clin Psychiatry 59(Suppl 5):5-12.
332. Thase ME, Entsuah AR, Rudolph RL (2001) Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178:234-241.
333. Thorpe L, Whitney DK, Kutcher SP, Kennedy SH; CANMAT Depression Work Group (2001) Clinical guidelines for the treatment of depressive disorders. VI. Special populations. Can J Psychiatry 46(Suppl 1):63S-76S.
334. Tignol J, Stoker MJ, Dunbar GC (1992) Paroxetine in the treatment of melancholia and severe depression. Int Clin Psychopharmacol 7:91-94.
335. Tollefson GD, Bosomworth JC, Heiligenstein JH, Potvin JH, Holman S (1995) A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression. The Fluoxetine Collaborative Study Group. Int Psychogeriatr 7:89-104.
336. Uehlinger C, Nil R, Amey B, Baumann P, Dufour H (1995) Citalopram-lithium combination treatment of elderly depressed patients: a pilot study. Int J Ger Psychiatry 10:281-287.
337. Unützer J, Patrick DL, Diehr P, Simon G, Crembowski D, Katon W (2000a) Quality adjusted life years in older adults with depressive symptoms and chronic medical disorders. Int Psychogeriatr 12:15-33.
338. Unützer J, Simon G, Belin TR, Datt M, Katon W, Patrick D (2000b) Care for depression in HMO patients aged 65 and older. J Am Geriatr Soc 48:871-878.
339. Üstün TB, Sartorius N (1995) Mental Illness in general health care: an international study. Wiley, Chichester.
340. Van den Hoofdakker RH, Gordijn, Kasper S (1994) Sleep deprivation in refractory depression. In: Nolen WA, Zohar J, Roose SP, Amsterdam JD (eds) Refractory Depression: Current Strategies and Future Directions. Wiley & Sons, Chichester, pp 129-142.
341. Versiani M, Oggero U, Alterwain P, Capponi R, Dajas F, Heinze-Martin C, Marquez CA, Poleo MA, Rivero-Almanzor LE, Rossel L, Schimid-Burgk W, Udabe RU (1989) A double-blind comparative trial of moclobemide v. imipramine and placebo in major depressive episodes. Br J Psychiatry (Suppl 6):72-77.
342. Wassermann EM (2000) Side effects of repetitive transcranial magnetic stimulation. Depress Anxiety 12:124-129.
343. Wells KB, Hays RD, Burnam MA, Rogers W, Greenfield S, Ware JE Jr. (1989a) Detection of depressive disorder for patients receiving prepaid or fee-for service care. Results from the Medical Outcomes Study. JAMA 262:3298-3302.
344. Wells KB, Stewart A, Hays RD, Burnam MA, Rogers W, Daniels M, Berry S, Greenfield S, Ware JE (1989b) The functioning and wellbeing of depressed patients. Results from the Medical Outcomes Study. JAMA 262:914-919.
345. Wiegand MH, Lauer CJ, Schreiber W (2001) Patterns of response to repeated total sleep deprivations in depression. J Affect Disord 64:257-260.
346. Wijeratne C, Halliday GS, Lyndon RW (1999) The present status of electroconvulsive therapy: a systematic review. Med J Aust 171:250-254.
347. Wilens TE, Biederman J, Baldessarini RJ, Geller B, Schleifer D, Spencer TJ, Birmaher B, Goldblatt A (1996) Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. J Am Acad Child Adolesc Psychiatry 35:1491-1501.
348. Williams JW Jr, Mulrow CD, Chiquette E, Noel PH, Aguilar C, Cornell J (2000) A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 132:743-756.
349. Wirz-Justice A, Van den Hoofdakker RH (1999) Sleep deprivation in depression: what do we know, where do we go? Biol Psychiatry 46:445-453.
350. Wirz-Justice A, Graw P, Krauchi K, Sarrafzadeh A, English J, Arendt J, Sand L (1996) 'Natural' light treatment of seasonal affective disorder. J Affect Disord 37:109-120.
351. Wisner KL, Perel JM, Findling RL (1996) Antidepressant treatment during breast-feeding. Am J Psychiatry 153:1132-1137.
352. Wisner KL, Gelenberg AJ, Leonard H, Zarin D, Frank E (1999) Pharmacologic treatment of depression during pregnancy. JAMA 282:1264-1269.
353. Wisner KL, Zarin DA, Holmboe ES, Appelbaum PS, Gelenberg AJ, Leonard HL, Frank E (2000) Risk-benefit decision making for treatment of depression during pregnancy. Am J Psychiatry 157:1933-1940.
354. Wittchen HU, Lieb R, Wunderlich U, Schuster P (1999) Comorbidity in primary care: presentation and consequences. J Clin Psychiatry 60(Suppl 7):29-36.
355. Wittchen HU (2000) Epidemiology of affective disorders. In: Helmchen H, Henn F, Lauter H, Sartorius N (eds) Contemporary Psychiatry. Vol. 3. Springer, Heidelberg, pp 231-241.
356. Wolkowitz OM, Reus VI (1999) Treatment of depression with antiglucocorticoid drugs. Psychosom Med 61:698-711.
357. Wolkowitz OM, Reus VI, Keebler A, Nelson N, Friedland M, Brizendine L, Roberts E (1999) Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry 156:646-649.
358. World Health Organization (1978) International Classification of Diseases. 9th revision. WHO, Geneva.
359. World Health Organization (1992) The ICD-10 Classification of Mental and Behavioural Disorders - Clinical Descriptions and Diagnostic Guidelines. WHO, Geneva.
360. Wu JC, Bunney WE (1990) The biological basis of an antidepressant response to sleep deprivation and relapse: review and hypothesis. Am J Psychiatry 147:14-21.
361. Wulsin LR, Vaillant GE, Wells VE (1999) A systematic review of the mortality of depression. Psychosom Med 61:6-17.
362. Young SN (1991) Use of tryptophan in combination with other antidepressant treatments: a review. J Psychiatry Neurosci 16:241-246.
363. Young AS, Klap R, Sherbourne CD, Wells KB (2001) The quality of care for depressive and anxiety disorders in the United States. Arch Gen Psychiatry 58:55-61.
364. Zajecka J (2001) Strategies for the treatment of antidepressantrelated sexual dysfunction. J. Clin Psychiatry 62(Suppl 3):35-43.
365. Zesiewicz TA, Gold M, Chari G, Hauser RA (1999) Current issues in depression in Parkinson's disease. Am J Geriatr Psychiatry 7:110-118.
366. Zimmer B, Rosen J, Thornton JE, Perel JM, Reynolds CF 3rd (1991) Adjunctive lithium carbonate in nortriptyline-resistant elderly depressed patients. J Clin Psychopharmacol 11:254-256.
367. Zinbarg RE, Barlow DH, Liebowitz M, Street L, Broadhead E, Katon W, Roy-Byrne P, Lepine JP, Teherani M, Richards J (1994) The DSM-IV field trial for mixed anxiety-depression. Am J Psychiatry 151:1153-1162.
368. Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, Holsboer F (2000) Effects of the high-affinity corticotropinreleasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 34:171-181.
369. Zohar J, Kaplan Z, Amsterdam JD (1991) Reserpine augmentation in resistant depression: a review. In: Amsterdam JD (ed) Advances in Neuropsychiatry and Psychopharmacology, Vol 2: Refractory Depression. Raven Press, New York, pp 219-222.
370. Zullino D, Baumann P (2001) Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhibitors. Pharmacopsychiatry 34:119-127.